Trial Profile
A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Deutetrabenazine (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- Acronyms ARTISTS 1
- Sponsors Teva Branded Pharmaceutical Products R&D
- 19 Feb 2020 Primary endpoint has not been met. (Change in the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS)), according to a Teva Pharmaceutical Industries media release.
- 19 Feb 2020 Results published in the Teva Pharmaceutical Industries Media Release
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.